{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T01:05:04Z","timestamp":1783991104019,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Coronavirus disease 2019 (COVID-19) is an acute respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Severe disease may require hospitalisation and respiratory support, which can cause longer-term morbidity. Patient utility data are limited, especially for severe disease where data collection can be challenging or unethical. A vignette study was designed to estimate utility values for COVID-19 disease states.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A sample of United Kingdom (UK)-based adults (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009500) completed the EQ-5D-5\u00a0L questionnaire for eight vignettes as patient proxies in September 2021. Vignettes qualitatively described hospitalisation and disease severity permutations, informed by a large UK-based COVID-19 infection survey. Recruitment was stratified to reflect UK demographics. EQ-5D utilities were derived using the appropriate UK value set.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Recovery without long-term sequelae had the highest utility (mean [standard deviation]: 0.87 [0.14]), followed by pre-infection (0.73 [0.22]). The intensive care unit state had the lowest utility (\u20130.38 [0.14]). Mild and moderate outpatient states reported similar utility (0.29 [0.26] vs. 0.31 [0.27]). The severe general hospital ward state had lower utility than the high dependency unit state (\u20130.18 [0.24] vs. \u2212\u20090.11 [0.25]). Recovery with long-term sequelae had low utility (0.21 [0.29]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mean utility values declined as COVID-19 disease state severity increased, suggesting that COVID-19 is likely to impact patient quality of life, in line with published literature. However, the evolving nature of COVID-19 may limit the generalisability of findings to the current disease landscape. Nevertheless, generation of utility values using a vignette-based approach represents a reasonable alternative where collection patient health-related quality of life data is infeasible, albeit with some limitations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13561-026-00781-5","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:04:29Z","timestamp":1779285869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health-related quality of life in COVID-19 in the United Kingdom: a vignette study"],"prefix":"10.1186","volume":"16","author":[{"given":"Dionysios","family":"Ntais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Ntim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Porteous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardik","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Puenpatom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"781_CR1","doi-asserted-by":"publisher","unstructured":"Bell E, Brassel S, Oliver E, Schirrmacher H, Arnetorp S, Berg K et al. Estimates of the Global Burden of COVID-19 and the Value of Broad and Equitable Access to COVID-19 Vaccines. Vaccines (Basel). 2022;10(8). https:\/\/doi.org\/10.3390\/vaccines10081320.","DOI":"10.3390\/vaccines10081320"},{"key":"781_CR2","unstructured":"World Health Organization. WHO COVID-19 dashboard. https:\/\/data.who.int\/dashboards\/covid19\/cases?n=c. Accessed April 15, 2024."},{"key":"781_CR3","unstructured":"GOV.UK. Coronavirus (COVID-19) in the UK. https:\/\/coronavirus.data.gov.uk\/. Accessed February 6, 2024."},{"key":"781_CR4","unstructured":"World Health Organization. Coronavirus disease (COVID-19) pandemic. https:\/\/www.who.int\/europe\/emergencies\/situations\/covid-19. Accessed February 12, 2024."},{"key":"781_CR5","unstructured":"NHS England. COVID-19 Hospital Activity. Available from: https:\/\/www.england.nhs.uk\/statistics\/statistical-work-areas\/covid-19-hospital-activity\/. Accessed February 3, 2026."},{"key":"781_CR6","doi-asserted-by":"publisher","unstructured":"Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MMG, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. Cochrane Database Syst Reviews. 2021(2). https:\/\/doi.org\/10.1002\/14651858.CD013665.pub3.","DOI":"10.1002\/14651858.CD013665.pub3"},{"key":"781_CR7","unstructured":"National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: Managing COVID-19 [NG191]. 2024. https:\/\/www.nice.org.uk\/guidance\/NG191."},{"key":"781_CR8","unstructured":"Department of Health and Social Care. Higher-risk patients eligible for COVID-19 treatments: independent advisory group report (March 2023). https:\/\/www.gov.uk\/government\/publications\/higher-risk-patients-eligible-for-covid-19-treatments-independent-advisory-group-report."},{"issue":"10","key":"781_CR9","doi-asserted-by":"publisher","first-page":"e0259164","DOI":"10.1371\/journal.pone.0259164","volume":"16","author":"AN Poudel","year":"2021","unstructured":"Poudel AN, Zhu S, Cooper N, Roderick P, Alwan N, Tarrant C, et al. Impact of Covid-19 on health-related quality of life of patients: A structured review. PLoS ONE. 2021;16(10):e0259164.","journal-title":"PLoS ONE"},{"key":"781_CR10","doi-asserted-by":"publisher","first-page":"n1648","DOI":"10.1136\/bmj.n1648","volume":"374","author":"H Crook","year":"2021","unstructured":"Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648.","journal-title":"BMJ"},{"issue":"2","key":"781_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S2215-0366(20)30462-4","volume":"8","author":"M Taquet","year":"2021","unstructured":"Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62\u2008354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130\u201340.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"781_CR12","doi-asserted-by":"publisher","first-page":"20795","DOI":"10.1038\/s41598-022-24240-3","volume":"12","author":"S Wilding","year":"2022","unstructured":"Wilding S, O\u2019Connor DB, Ferguson E, Cleare S, Wetherall K, O\u2019Carroll RE, et al. Probable COVID-19 infection is associated with subsequent poorer mental health and greater loneliness in the UK COVID-19 Mental Health and Wellbeing study. Sci Rep. 2022;12(1):20795.","journal-title":"Sci Rep"},{"issue":"1","key":"781_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s41256-022-00246-2","volume":"7","author":"S Mohsen","year":"2022","unstructured":"Mohsen S, El-Masry R, Ali OF, Abdel-Hady D. Quality of life during COVID-19 pandemic: a community-based study in Dakahlia governorate, Egypt. Glob Health Res Policy. 2022;7(1):15.","journal-title":"Glob Health Res Policy"},{"key":"781_CR14","unstructured":"National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual. January 2022. https:\/\/www.nice.org.uk\/process\/pmg36\/."},{"key":"781_CR15","unstructured":"National Institute for Health and Care Excellence (NICE). Final Draft Guidance: Therapeutics for people with COVID-19 [TA878]. February 2023. https:\/\/www.nice.org.uk\/guidance\/TA878."},{"key":"781_CR16","doi-asserted-by":"crossref","unstructured":"Warnants E, Thurtle E, Ruban-Fell B, Griffiths A. Approaches to the Collection of Utility Values for Rare Diseases: A Cross-Country Comparison. Poster presented at: Virtual ISPOR Europe. 2020 Congress 16\u201319 November. https:\/\/www.valueinhealthjournal.com\/.","DOI":"10.1016\/j.jval.2020.08.1822"},{"issue":"2","key":"781_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","volume":"41","author":"M Hern\u00e1ndez Alava","year":"2023","unstructured":"Hern\u00e1ndez Alava M, Pudney S, Wailoo A. Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study. PharmacoEconomics. 2023;41(2):199\u2013207.","journal-title":"PharmacoEconomics"},{"issue":"3","key":"781_CR18","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1016\/j.bja.2020.12.007","volume":"126","author":"M Taboada","year":"2021","unstructured":"Taboada M, Moreno E, Cari\u00f1ena A, Rey T, Pita-Romero R, Leal S, et al. Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients. Br J Anaesth. 2021;126(3):e110\u20133.","journal-title":"Br J Anaesth"},{"issue":"5","key":"781_CR19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jinf.2021.01.002","volume":"82","author":"AM Garratt","year":"2021","unstructured":"Garratt AM, Ghanima W, Einvik G, Stavem K. Quality of life after COVID-19 without hospitalisation: Good overall, but reduced in some dimensions. J Infect. 2021;82(5):186\u2013230.","journal-title":"J Infect"},{"issue":"6","key":"781_CR20","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2020.12.017","volume":"24","author":"LS Matza","year":"2021","unstructured":"Matza LS, Stewart KD, Lloyd AJ, Rowen D, Brazier JE. Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations. Value Health. 2021;24(6):812\u201321.","journal-title":"Value Health"},{"key":"781_CR21","unstructured":"Rowen D, Brazier J, Wong R, Wailoo A. Measuring and valuing health-related quality of life when sufficient EQ-5D data is not available. Report by the Decision Support Unit; 2020. https:\/\/sheffield.ac.uk\/nice-dsu\/tsds\/full-list."},{"key":"781_CR22","unstructured":"Study Sponsor. Clinical Trial Protocol. 2021. https:\/\/clinicaltrials.gov\/study\/NCT04575597?tab=researcher."},{"key":"781_CR23","doi-asserted-by":"crossref","unstructured":"Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Mart\u00edn-Quir\u00f3s A, Caraco Y, Williams-Diaz A, Brown ML, Du J. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. New Engl J Med. 2022;386(6):509\u201320. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2116044.","DOI":"10.1056\/NEJMoa2116044"},{"key":"781_CR24","unstructured":"Office for National Statistics (ONS). Coronavirus (COVID-19) Infection Survey: England. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/datasets\/coronaviruscovid19infectionsurveydata. Accessed June 30, 2021."},{"key":"781_CR25","unstructured":"Office for National Statistics (ONS). Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk\/1april 2021. Accessed June 30, 2021."},{"key":"781_CR26","doi-asserted-by":"publisher","unstructured":"Abdukahil SA, Abe R, Abel L, Absil L, Acker A, Adachi S, et al. COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. Infection. 2021. https:\/\/doi.org\/10.1007\/s15010-021-01599-5.","DOI":"10.1007\/s15010-021-01599-5"},{"key":"781_CR27","unstructured":"Study Sponsor. COVID-19 systematic literature review for dossier development. 2021. https:\/\/www.nice.org.uk\/guidance\/ta1056."},{"issue":"10","key":"781_CR28","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"7","key":"781_CR29","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","volume":"22","author":"MF Janssen","year":"2013","unstructured":"Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717\u201327.","journal-title":"Qual Life Res"},{"key":"781_CR30","doi-asserted-by":"publisher","first-page":"e071932","DOI":"10.1136\/bmj-2022-071932","volume":"379","author":"B Zheng","year":"2022","unstructured":"Zheng B, Green ACA, Tazare J, Curtis HJ, Fisher L, Nab L, et al. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform. BMJ. 2022;379:e071932.","journal-title":"BMJ"},{"issue":"1","key":"781_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12955-024-02230-5","volume":"22","author":"IA Soare","year":"2024","unstructured":"Soare IA, Ansari W, Nguyen JL, Mendes D, Ahmed W, Atkinson J, et al. Health-related quality of life in mild-to-moderate COVID-19 in the UK: a cross-sectional study from pre- to post-infection. Health Qual Life Outcomes. 2024;22(1):12.","journal-title":"Health Qual Life Outcomes"},{"key":"781_CR32","doi-asserted-by":"publisher","unstructured":"Png ME, Harris V, Grabey J, Hart ND, Jani BD, Butler D et al. Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial. Br J Gen Pract. 2024. https:\/\/doi.org\/10.3399\/BJGP.2023.0444.","DOI":"10.3399\/BJGP.2023.0444"},{"issue":"1","key":"781_CR33","doi-asserted-by":"publisher","first-page":"e962","DOI":"10.1093\/cid\/ciac151","volume":"75","author":"FG Sandmann","year":"2022","unstructured":"Sandmann FG, Tessier E, Lacy J, Kall M, Van Leeuwen E, Charlett A, et al. Long-Term Health-Related Quality of Life in Non-Hospitalized Coronavirus Disease 2019 (COVID-19) Cases With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in England: Longitudinal Analysis and Cross-Sectional Comparison With Controls. Clin Infect Dis. 2022;75(1):e962\u201373.","journal-title":"Clin Infect Dis"},{"key":"781_CR34","unstructured":"National Institute for Health and Care Excellence (NICE). Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19. Available from: https:\/\/www.nice.org.uk\/guidance\/ta878. Accessed February 3, 2026."},{"issue":"1","key":"781_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s41687-023-00572-0","volume":"7","author":"CR Tak","year":"2023","unstructured":"Tak CR. The health impact of long COVID: a cross-sectional examination of health-related quality of life, disability, and health status among individuals with self-reported post-acute sequelae of SARS CoV-2 infection at various points of recovery. J Patient Rep Outcomes. 2023;7(1):31.","journal-title":"J Patient Rep Outcomes"},{"key":"781_CR36","doi-asserted-by":"publisher","unstructured":"Carlile O, Briggs A, Henderson AD, Butler-Cole BF, Tazare J, Tomlinson LA, et al. Impact of Long COVID on Health-Related Quality-of-Life using OpenPROMPT. Lancet Reg Health Eur. 2024;40. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100908.","DOI":"10.1016\/j.lanepe.2024.100908"}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-026-00781-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00781-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00781-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:23:40Z","timestamp":1783988620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13561-026-00781-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["781"],"URL":"https:\/\/doi.org\/10.1186\/s13561-026-00781-5","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants confirmed consent to proceed with survey participation, acknowledging that since data were anonymised, it was not possible to withdraw consent following survey completion. However, as this was a non-interventional study and participant data remained anonymous, informed consent was not sought. The study protocol was reviewed by MSD\u2019s Document Review Committee, which served as an independent ethics review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DN, SB, VC, and VN are employees of Merck Sharp & Dohme (UK) Limited, London, UK and may also hold company shares. APu and HG are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may also hold company shares. APo, AN and JP are employees of Costello Medical Ltd., a company which received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA to conduct this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}